{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:14:19Z","timestamp":1793247259423,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00705-025-06381-8","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T02:51:26Z","timestamp":1755571886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacological advances in HIV treatment: from ART to long-acting injectable therapies"],"prefix":"10.1007","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1617-8426","authenticated-orcid":false,"given":"Krzysztof","family":"\u0141upina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9190-1193","authenticated-orcid":false,"given":"Klaudia","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5322-0115","authenticated-orcid":false,"given":"Dominika","family":"Lorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3726-803X","authenticated-orcid":false,"given":"Adrian","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7609-859X","authenticated-orcid":false,"given":"Anna","family":"Romac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5228-0042","authenticated-orcid":false,"given":"Ewelina","family":"G\u0142owacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7977-9797","authenticated-orcid":false,"given":"Jakub","family":"Janczura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"6381_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41572-023-00452-3","volume":"9","author":"L-G Bekker","year":"2023","unstructured":"Bekker L-G, Beyrer C, Mgodi N et al (2023) HIV infection. Nat Rev Dis Primers 9:42","journal-title":"Nat Rev Dis Primers"},{"key":"6381_CR2","unstructured":"HIV and AIDS. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids. Accessed 11 Mar 2025"},{"key":"6381_CR3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3390\/ph17070887","volume":"17","author":"Y Sun","year":"2024","unstructured":"Sun Y, Wang L (2024) Development of anti-HIV therapeutics: From conventional drug discovery to cutting-edge technology. Pharmaceuticals (Basel) 17:887","journal-title":"Pharmaceuticals (Basel)"},{"key":"6381_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s11904-022-00627-9","volume":"19","author":"G Ransley","year":"2022","unstructured":"Ransley G, Zimba S, Gadama Y et al (2022) Trends and clinical characteristics of HIV and cerebrovascular disease in low- and middle-income countries (LMICs) between 1990 and 2021. Curr HIV\/AIDS Rep 19:548\u2013565","journal-title":"Curr HIV\/AIDS Rep"},{"key":"6381_CR5","doi-asserted-by":"publisher","unstructured":"Foka FET, Mufhandu HT (2023) Current ARTs, virologic failure, and implications for AIDS management: a systematic review. Viruses 15. https:\/\/doi.org\/10.3390\/v15081732","DOI":"10.3390\/v15081732"},{"key":"6381_CR6","doi-asserted-by":"publisher","first-page":"e0262926","DOI":"10.1371\/journal.pone.0262926","volume":"17","author":"O Jolayemi","year":"2022","unstructured":"Jolayemi O, Bogart LM, Storholm ED et al (2022) Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: A qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. PLoS ONE 17:e0262926","journal-title":"PLoS ONE"},{"key":"6381_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/QCO.0000000000000803","volume":"35","author":"MJ Lee","year":"2022","unstructured":"Lee MJ, Fidler S, Frater J (2022) Immunotherapeutic approaches to HIV cure and remission. Curr Opin Infect Dis 35:31\u201341","journal-title":"Curr Opin Infect Dis"},{"key":"6381_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/1040841X.2021.1902941","volume":"47","author":"S Yandrapally","year":"2021","unstructured":"Yandrapally S, Mohareer K, Arekuti G et al (2021) HIV co-receptor-tropism: cellular and molecular events behind the enigmatic co-receptor switching. Crit Rev Microbiol 47:499\u2013516","journal-title":"Crit Rev Microbiol"},{"key":"6381_CR9","doi-asserted-by":"publisher","unstructured":"Masenga SK, Mweene BC, Luwaya E et al (2023) HIV-host cell interactions. Cells 12. https:\/\/doi.org\/10.3390\/cells12101351","DOI":"10.3390\/cells12101351"},{"key":"6381_CR10","doi-asserted-by":"publisher","unstructured":"Katusiime MG, Neer V, Guo S et al (2025) Divergent populations of HIV-infected naive and memory CD4+ T cell clones in children on antiretroviral therapy. J Clin Invest 135. https:\/\/doi.org\/10.1172\/jci188533","DOI":"10.1172\/jci188533"},{"key":"6381_CR11","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1371\/journal.ppat.0030058","volume":"3","author":"K Oswald-Richter","year":"2007","unstructured":"Oswald-Richter K, Grill SM, Leelawong M et al (2007) Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog 3:e58","journal-title":"PLoS Pathog"},{"key":"6381_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/v14051027","volume":"14","author":"AK Singh","year":"2022","unstructured":"Singh AK, Das K (2022) Insights into HIV-1 reverse transcriptase (RT) inhibition and drug resistance from thirty years of structural studies. Viruses 14:1027","journal-title":"Viruses"},{"key":"6381_CR13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/v14050926","volume":"14","author":"AN Engelman","year":"2022","unstructured":"Engelman AN, Kvaratskhelia M (2022) Multimodal functionalities of HIV-1 integrase. Viruses 14:926","journal-title":"Viruses"},{"key":"6381_CR14","doi-asserted-by":"publisher","unstructured":"Tabler CO, Tilton JC (2024) Mechanism and kinetics of HIV-1 protease activation. Viruses 16:. https:\/\/doi.org\/10.3390\/v16121826","DOI":"10.3390\/v16121826"},{"key":"6381_CR15","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3389\/fimmu.2019.02485","volume":"10","author":"A Mart\u00edn-Moreno","year":"2019","unstructured":"Mart\u00edn-Moreno A, Mu\u00f1oz-Fern\u00e1ndez MA (2019) Dendritic cells, the double agent in the war against HIV-1. Front Immunol 10:2485","journal-title":"Front Immunol"},{"key":"6381_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/jnc.15336","volume":"158","author":"S Valdebenito","year":"2021","unstructured":"Valdebenito S, Castellano P, Ajasin D, Eugenin EA (2021) Astrocytes are HIV reservoirs in the brain: a cell type with poor HIV infectivity and replication but efficient cell-to-cell viral transfer. J Neurochem 158:429\u2013443","journal-title":"J Neurochem"},{"key":"6381_CR17","doi-asserted-by":"publisher","unstructured":"Nickoloff-Bybel EA, Festa L, Meucci O, Gaskill PJ (2021) Co-receptor signaling in the pathogenesis of neuroHIV. Retrovirology 18. https:\/\/doi.org\/10.1186\/s12977-021-00569-x","DOI":"10.1186\/s12977-021-00569-x"},{"key":"6381_CR18","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","volume":"382","author":"M Kozal","year":"2020","unstructured":"Kozal M, Aberg J, Pialoux G et al (2020) Fostemsavir in adults with multidrug-resistant HIV-1 infection. N Engl J Med 382:1232\u20131243","journal-title":"N Engl J Med"},{"key":"6381_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/1060028020942218","volume":"55","author":"EB Chahine","year":"2021","unstructured":"Chahine EB, Durham SH (2021) Ibalizumab: The first monoclonal antibody for the treatment of HIV-1 infection. Ann Pharmacother 55:230\u2013239","journal-title":"Ann Pharmacother"},{"key":"6381_CR20","doi-asserted-by":"publisher","first-page":"114859","DOI":"10.1016\/j.bcp.2021.114859","volume":"195","author":"S Singh","year":"2022","unstructured":"Singh S, Bruder-Nascimento A, Belin de Chantemele EJ, Bruder-Nascimento T (2022) CCR5 antagonist treatment inhibits vascular injury by regulating NADPH oxidase 1. Biochem Pharmacol 195:114859","journal-title":"Biochem Pharmacol"},{"key":"6381_CR21","doi-asserted-by":"publisher","first-page":"114554","DOI":"10.1016\/j.ejmech.2022.114554","volume":"240","author":"F Amblard","year":"2022","unstructured":"Amblard F, Patel D, Michailidis E et al (2022) HIV nucleoside reverse transcriptase inhibitors. Eur J Med Chem 240:114554","journal-title":"Eur J Med Chem"},{"key":"6381_CR22","doi-asserted-by":"publisher","first-page":"114217","DOI":"10.1016\/j.ejmech.2022.114217","volume":"233","author":"J Popovi\u0107-Djordjevi\u0107","year":"2022","unstructured":"Popovi\u0107-Djordjevi\u0107 J, Quispe C, Giordo R et al (2022) Natural products and synthetic analogues against HIV: A perspective to develop new potential anti-HIV drugs. Eur J Med Chem 233:114217","journal-title":"Eur J Med Chem"},{"key":"6381_CR23","unstructured":"FDA-approved HIV medicines. https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/fda-approved-hiv-medicines. Accessed 24 Feb 2025"},{"key":"6381_CR24","doi-asserted-by":"publisher","unstructured":"Vanangamudi M, Palaniappan S, Kathiravan MK, Namasivayam V (2023) Strategies in the design and development of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Viruses 15. https:\/\/doi.org\/10.3390\/v15101992","DOI":"10.3390\/v15101992"},{"key":"6381_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.coph.2020.10.009","volume":"54","author":"M Vanangamudi","year":"2020","unstructured":"Vanangamudi M, Kurup S, Namasivayam V (2020) Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens. Curr Opin Pharmacol 54:179\u2013187","journal-title":"Curr Opin Pharmacol"},{"key":"6381_CR26","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2174\/1568026619666190619115243","volume":"19","author":"C Voshavar","year":"2019","unstructured":"Voshavar C (2019) Protease inhibitors for the treatment of HIV\/AIDS: recent advances and future challenges. Curr Top Med Chem 19:1571\u20131598","journal-title":"Curr Top Med Chem"},{"key":"6381_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.chom.2019.06.010","volume":"26","author":"DA Collier","year":"2019","unstructured":"Collier DA, Monit C, Gupta RK (2019) The impact of HIV-1 drug escape on the global treatment landscape. Cell Host Microbe 26:48\u201360","journal-title":"Cell Host Microbe"},{"key":"6381_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12977-022-00608-1","volume":"19","author":"AV Zhao","year":"2022","unstructured":"Zhao AV, Crutchley RD, Guduru RC et al (2022) A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology 19:22","journal-title":"Retrovirology"},{"key":"6381_CR29","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/hiv.13542","volume":"24","author":"J Ambrosioni","year":"2023","unstructured":"Ambrosioni J, Levi L, Alagaratnam J et al (2023) Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med 24:1126\u20131136","journal-title":"HIV Med"},{"key":"6381_CR30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","volume":"83","author":"P Cahn","year":"2020","unstructured":"Cahn P, Madero JS, Arribas JR et al (2020) Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment\u2013naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr 83:310\u2013318","journal-title":"J Acquir Immune Defic Syndr"},{"key":"6381_CR31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/QAD.0000000000002851","volume":"35","author":"P Ackerman","year":"2021","unstructured":"Ackerman P, Thompson M, Molina J-M et al (2021) Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS 35:1061\u20131072","journal-title":"AIDS"},{"key":"6381_CR32","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa1711460","volume":"379","author":"B Emu","year":"2018","unstructured":"Emu B, Fessel J, Schrader S et al (2018) Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med 379:645\u2013654","journal-title":"N Engl J Med"},{"key":"6381_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-021-01005-1","volume":"60","author":"D Hodge","year":"2021","unstructured":"Hodge D, Back DJ, Gibbons S et al (2021) Pharmacokinetics and drug\u2013drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet 60:835\u2013853","journal-title":"Clin Pharmacokinet"},{"key":"6381_CR34","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.15585\/mmwr.mm6940a1","volume":"69","author":"SM Crim","year":"2020","unstructured":"Crim SM, Tie Y, Beer L et al (2020) Barriers to antiretroviral therapy adherence among HIV-positive Hispanic and Latino men who have sex with men -United States, 2015\u20132019. MMWR Morb Mortal Wkly Rep 69:1437\u20131442","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6381_CR35","doi-asserted-by":"publisher","unstructured":"Johnson JE, Brotherton AL, Rossi MR et al (2025) Long-acting injectable antiretroviral therapy for treatment of human immunodeficiency virus: A review. Curr HIV\/AIDS Rep 22.https:\/\/doi.org\/10.1007\/s11904-025-00741-4","DOI":"10.1007\/s11904-025-00741-4"},{"key":"6381_CR36","unstructured":"Lenacapavir (HIV prevention) health professional drug record. https:\/\/clinicalinfo.hiv.gov\/en\/drugs\/lenacapavir-hiv-prevention\/health-professional. Accessed 6 May 2025"},{"key":"6381_CR37","unstructured":"Cabenuva patient drug record. https:\/\/clinicalinfo.hiv.gov\/en\/drugs\/cabotegravir-rilpivirine\/patient. Accessed 6 May 2025"},{"key":"6381_CR38","unstructured":"Islatravir health professional drug record. https:\/\/clinicalinfo.hiv.gov\/en\/drugs\/islatravir\/health-professional. Accessed 6 May 2025"},{"key":"6381_CR39","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s11904-022-00616-y","volume":"19","author":"UM Parikh","year":"2022","unstructured":"Parikh UM, Koss CA, Mellors JW (2022) Long-acting injectable cabotegravir for HIV prevention: What do we know and need to know about the risks and consequences of cabotegravir resistance? Curr HIV\/AIDS Rep 19:384\u2013393","journal-title":"Curr HIV\/AIDS Rep"},{"key":"6381_CR40","doi-asserted-by":"publisher","first-page":"105032","DOI":"10.1016\/j.jcv.2021.105032","volume":"146","author":"OE Ariyo","year":"2022","unstructured":"Ariyo OE, Jones CE (2022) Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review. J Clin Virol 146:105032","journal-title":"J Clin Virol"},{"key":"6381_CR41","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva J-F, Richmond GJ et al (2020) Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med 382:1112\u20131123","journal-title":"N Engl J Med"},{"key":"6381_CR42","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cid\/ciad020","volume":"76","author":"ET Overton","year":"2023","unstructured":"Overton ET, Richmond G, Rizzardini G et al (2023) Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis 76:1646\u20131654","journal-title":"Clin Infect Dis"},{"key":"6381_CR43","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","volume":"8","author":"C Orkin","year":"2021","unstructured":"Orkin C, Oka S, Philibert P et al (2021) Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV 8:e185\u2013e196","journal-title":"Lancet HIV"},{"key":"6381_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/COH.0000000000000713","volume":"17","author":"H Dvory-Sobol","year":"2022","unstructured":"Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS (2022) Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS 17:15\u201321","journal-title":"Curr Opin HIV AIDS"},{"key":"6381_CR45","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.1021\/acs.molpharmaceut.3c00626","volume":"20","author":"R Subramanian","year":"2023","unstructured":"Subramanian R, Tang J, Zheng J et al (2023) Lenacapavir: A novel, potent, and selective first-in-class inhibitor of HIV-1 capsid function exhibits optimal pharmacokinetic properties for a long-acting injectable antiretroviral agent. Mol Pharm 20:6213\u20136225","journal-title":"Mol Pharm"},{"key":"6381_CR46","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer S, DeJesus E, Stellbrink H-J et al (2022) Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med 386:1793\u20131803","journal-title":"N Engl J Med"},{"key":"6381_CR47","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"L-G Bekker","year":"2024","unstructured":"Bekker L-G, Das M, Abdool Karim Q et al (2024) Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med 391:1179\u20131192","journal-title":"N Engl J Med"},{"key":"6381_CR48","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1111\/bcp.16097","volume":"90","author":"T Senneker","year":"2024","unstructured":"Senneker T (2024) Drug-drug interactions between gender-affirming hormone therapy and antiretrovirals for treatment\/prevention of HIV. Br J Clin Pharmacol 90:2366\u20132382","journal-title":"Br J Clin Pharmacol"},{"key":"6381_CR49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858","author":"CF Kelley","year":"2024","unstructured":"Kelley CF, Acevedo-Qui\u00f1ones M, Agwu AL et al (2024) Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2411858","journal-title":"N Engl J Med"},{"key":"6381_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00405-2","author":"V Jogiraju","year":"2025","unstructured":"Jogiraju V, Pawar P, Yager J et al (2025) Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. Lancet. https:\/\/doi.org\/10.1016\/s0140-6736(25)00405-2","journal-title":"Lancet"},{"key":"6381_CR51","doi-asserted-by":"publisher","unstructured":"Diamond TL, Ngo W, Xu M et al (2022) Islatravir has a high barrier to resistance and exhibits a differentiated resistance profile from approved nucleoside reverse transcriptase inhibitors (NRTIs). Antimicrob Agents Chemother 66.https:\/\/doi.org\/10.1128\/aac.00133-22","DOI":"10.1128\/aac.00133-22"},{"key":"6381_CR52","doi-asserted-by":"publisher","unstructured":"Zang X, Ankrom W, Kraft WK et al (2024) Intracellular islatravir-triphosphate half-life supports extended dosing intervals. Antimicrob Agents Chemother 68. https:\/\/doi.org\/10.1128\/aac.00458-24","DOI":"10.1128\/aac.00458-24"},{"key":"6381_CR53","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41591-021-01479-3","volume":"27","author":"RP Matthews","year":"2021","unstructured":"Matthews RP, Patel M, Barrett SE et al (2021) Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial. Nat Med 27:1712\u20131717","journal-title":"Nat Med"},{"key":"6381_CR54","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/QAI.0000000000003135","volume":"92","author":"RP Matthews","year":"2023","unstructured":"Matthews RP, Zang X, Barrett SE et al (2023) A randomized, double-blind, placebo-controlled, phase 1 trial of radiopaque islatravir-eluting subdermal implants for pre-exposure prophylaxis against HIV-1 infection. J Acquir Immune Defic Syndr 92:310\u2013316","journal-title":"J Acquir Immune Defic Syndr"},{"key":"6381_CR55","doi-asserted-by":"publisher","unstructured":"Vivian Tsai Y, Pizzuti M, Deaney M et al (2022) 2069. Prevalence of cabotegravir and rilpivirine resistance associated mutations Among treatment experienced patients in a South Carolina outpatient clinic. Open Forum Infect Dis 9. https:\/\/doi.org\/10.1093\/ofid\/ofac492.1691","DOI":"10.1093\/ofid\/ofac492.1691"},{"key":"6381_CR56","doi-asserted-by":"publisher","first-page":"105427","DOI":"10.1016\/j.antiviral.2022.105427","volume":"208","author":"S-Y Rhee","year":"2022","unstructured":"Rhee S-Y, Parkin N, Harrigan PR et al (2022) Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir. Antiviral Res 208:105427","journal-title":"Antiviral Res"},{"key":"6381_CR57","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/infdis\/jiaf050","volume":"231","author":"NA Margot","year":"2025","unstructured":"Margot NA, Jogiraju V, Pennetzdorfer N et al (2025) Resistance analyses in heavily treatment-experienced people with HIV treated with the novel HIV capsid inhibitor lenacapavir after 2 years. J Infect Dis 231:1239\u20131245","journal-title":"J Infect Dis"},{"key":"6381_CR58","doi-asserted-by":"publisher","unstructured":"Byun H, Papathanasopoulos MA, Steegen K, Basson AE (2024) Thymidine analogue mutations with M184V significantly decrease phenotypic susceptibility of HIV-1 subtype C reverse transcriptase to islatravir. Viruses 16.https:\/\/doi.org\/10.3390\/v16121888","DOI":"10.3390\/v16121888"},{"key":"6381_CR59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1124\/jpet.124.002302","volume":"391","author":"J Zheng","year":"2024","unstructured":"Zheng J, Lu B, Carr G et al (2024) Lenacapavir exhibits atropisomerism\u2014mechanistic pharmacokinetics and disposition studies of lenacapavir reveal intestinal excretion as a major clearance pathway. J Pharmacol Exp Ther 391:91\u2013103","journal-title":"J Pharmacol Exp Ther"},{"key":"6381_CR60","doi-asserted-by":"publisher","unstructured":"Matthews RP, Cao Y, Patel M et al (2022) Safety and pharmacokinetics of islatravir in individuals with severe renal insufficiency. Antimicrob Agents Chemother 66. https:\/\/doi.org\/10.1128\/aac.00931-22","DOI":"10.1128\/aac.00931-22"},{"key":"6381_CR61","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1097\/QAD.0000000000003704","volume":"37","author":"JG O\u2019Shea","year":"2023","unstructured":"O\u2019Shea JG, Cholli P, Heil EL, Buchacz K (2023) Considerations for long-acting antiretroviral therapy in older persons with HIV. AIDS 37:2271\u20132286","journal-title":"AIDS"},{"key":"6381_CR62","first-page":"204993612211497","volume":"10","author":"M Brizzi","year":"2023","unstructured":"Brizzi M, P\u00e9rez SE, Michienzi SM, Badowski ME (2023) Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment? Ther Adv Infect Dis 10:20499361221149772","journal-title":"Ther Adv Infect Dis"},{"key":"6381_CR63","unstructured":"Rana LI, Zheng L, Bao Y (2024) Long-acting injectable CAB\/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359. In: Paper presented at: conference on retroviruses and opportunistic infections (CROI). Denver, CO"},{"key":"6381_CR64","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","volume":"10","author":"JB Nachega","year":"2023","unstructured":"Nachega JB, Scarsi KK, Gandhi M et al (2023) Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV 10:e332\u2013e342","journal-title":"Lancet HIV"},{"key":"6381_CR65","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/biomedicines13020493","volume":"13","author":"M Lanzafame","year":"2025","unstructured":"Lanzafame M, Mori G, Vento S (2025) Advances in HIV treatment: Long-acting antiretrovirals and the path toward a cure. Biomedicines 13:493","journal-title":"Biomedicines"},{"key":"6381_CR66","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-022-01786-0","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik J (2022) Lenacapavir: First approval. Drugs 82:1499\u20131504","journal-title":"Drugs"},{"key":"6381_CR67","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12879-025-10499-0","volume":"25","author":"V Iannone","year":"2025","unstructured":"Iannone V, Rossotti R, Bana NB et al (2025) Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data. BMC Infect Dis 25:105","journal-title":"BMC Infect Dis"},{"key":"6381_CR68","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1093\/jac\/dkae348","volume":"79","author":"V H\u00e9mar","year":"2024","unstructured":"H\u00e9mar V, Bouchet S, Ribeiro E et al (2024) A case of lenacapavir use for preventing mother-to-child HIV transmission. J Antimicrob Chemother 79:3354\u20133355","journal-title":"J Antimicrob Chemother"},{"key":"6381_CR69","unstructured":".https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/pediatric-arv. Accessed 26 Mar 2025"},{"key":"6381_CR70","unstructured":"Study details - Gilead Clinical trials. https:\/\/www.gileadclinicaltrials.com\/study?nctid=NCT06532656. Accessed 26 Mar 2025"},{"key":"6381_CR71","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1016\/S2666-5247(22)00009-X","volume":"3","author":"P Venkatesan","year":"2022","unstructured":"Venkatesan P (2022) Long-acting injectable ART for HIV: a (cautious) step forward. Lancet Microbe 3:e94","journal-title":"Lancet Microbe"},{"key":"6381_CR72","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/apc.2024.0067","volume":"38","author":"RJ Fisk-Hoffman","year":"2024","unstructured":"Fisk-Hoffman RJ, Ranger SS, Gracy A et al (2024) Perspectives among health care providers and people with HIV on the implementation of long-acting injectable cabotegravir\/rilpivirine for antiretroviral therapy in Florida. AIDS Patient Care STDS 38:275\u2013285","journal-title":"AIDS Patient Care STDS"},{"key":"6381_CR73","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/14656566.2023.2294918","volume":"24","author":"J Doan","year":"2023","unstructured":"Doan J, Brunzo-Hager S, Satterly B, Cory TJ (2023) Expanding therapeutic options: lenacapavir + bictegravir as a potential treatment for HIV. Expert Opin Pharmacother 24:1949\u20131956","journal-title":"Expert Opin Pharmacother"},{"key":"6381_CR74","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11904-020-00519-w","volume":"17","author":"A Kapoor","year":"2020","unstructured":"Kapoor A, Tan CS (2020) Immunotherapeutics to treat HIV in the central nervous system. Curr HIV\/AIDS Rep 17:499\u2013506","journal-title":"Curr HIV\/AIDS Rep"},{"key":"6381_CR75","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3390\/cells10092227","volume":"10","author":"V Castelli","year":"2021","unstructured":"Castelli V, Lombardi A, Palomba E et al (2021) Immune checkpoint inhibitors in people living with HIV\/AIDS: Facts and controversies. Cells 10:2227","journal-title":"Cells"},{"key":"6381_CR76","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/imr.13388","volume":"328","author":"HAD King","year":"2024","unstructured":"King HAD, Lewin SR (2024) Immune checkpoint inhibitors in infectious disease. Immunol Rev 328:350\u2013371","journal-title":"Immunol Rev"},{"key":"6381_CR77","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1200\/JCO.22.02459","volume":"41","author":"E Zarif","year":"2023","unstructured":"Zarif E (2023) Safety and activity of immune checkpoint inhibitors in people living With HIV and cancer: a real-world report from the cancer therapy using checkpoint inhibitors in people living with HIV-International (CATCH-IT) consortium. J Clin Oncol 41:3712\u20133723","journal-title":"J Clin Oncol"},{"key":"6381_CR78","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","volume":"606","author":"C Gaebler","year":"2022","unstructured":"Gaebler C, Nogueira L, Stoffel E et al (2022) Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 606:368\u2013374","journal-title":"Nature"},{"key":"6381_CR79","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3390\/v16060911","volume":"16","author":"JJ Thavarajah","year":"2024","unstructured":"Thavarajah JJ, H\u00f8nge BL, Wejse CM (2024) The use of broadly neutralizing antibodies (bNAbs) in HIV-1 treatment and prevention. Viruses 16:911","journal-title":"Viruses"},{"key":"6381_CR80","doi-asserted-by":"publisher","unstructured":"Matsui Y, Miura Y (2023) Advancements in cell-based therapies for HIV cure. Cells 13.https:\/\/doi.org\/10.3390\/cells13010064","DOI":"10.3390\/cells13010064"},{"key":"6381_CR81","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/v15030789","volume":"15","author":"G Campos-Gonzalez","year":"2023","unstructured":"Campos-Gonzalez G, Martinez-Picado J, Velasco-Hernandez T, Salgado M (2023) Opportunities for CAR-T cell immunotherapy in HIV cure. Viruses 15:789","journal-title":"Viruses"},{"key":"6381_CR82","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/vaccines9091026","volume":"9","author":"A Hargrave","year":"2021","unstructured":"Hargrave A, Mustafa AS, Hanif A et al (2021) Current status of HIV-1 vaccines. Vaccines (Basel) 9:1026","journal-title":"Vaccines (Basel)"},{"key":"6381_CR83","doi-asserted-by":"publisher","first-page":"2147912","DOI":"10.1155\/2024\/2147912","volume":"2024","author":"M Libera","year":"2024","unstructured":"Libera M, Caputo V, Laterza G et al (2024) The question of HIV vaccine: Why is a solution not yet available? J Immunol Res 2024:2147912","journal-title":"J Immunol Res"},{"key":"6381_CR84","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/S2352-3018(23)00264-3","volume":"11","author":"JP Nkolola","year":"2024","unstructured":"Nkolola JP, Barouch DH (2024) Prophylactic HIV-1 vaccine trials: past, present, and future. Lancet HIV 11:e117\u2013e124","journal-title":"Lancet HIV"},{"key":"6381_CR85","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/infdis\/jiac260","volume":"226","author":"Z Moodie","year":"2022","unstructured":"Moodie Z, Dintwe O, Sawant S et al (2022) Analysis of the HIV Vaccine Trials Network 702 phase 2b\u20133 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk. J Infect Dis 226:246\u2013257","journal-title":"J Infect Dis"},{"key":"6381_CR86","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey L, Gilbert PB, Juraska M et al (2021) Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med 384:1003\u20131014","journal-title":"N Engl J Med"},{"key":"6381_CR87","doi-asserted-by":"publisher","first-page":"eadd6502","DOI":"10.1126\/science.add6502","volume":"378","author":"DJ Leggat","year":"2022","unstructured":"Leggat DJ, Cohen KW, Willis JR et al (2022) Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 378:eadd6502","journal-title":"Science"},{"key":"6381_CR88","first-page":"100374","volume":"4","author":"C Sun","year":"2023","unstructured":"Sun C, Zuo T, Wen Z (2023) First clinical study of germline-targeting strategy: One step closer to a successful bnAb-based HIV vaccine. Innovation (Camb) 4:100374","journal-title":"Innovation (Camb)"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-025-06381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-025-06381-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-025-06381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T15:02:14Z","timestamp":1757689334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-025-06381-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":88,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6381"],"URL":"https:\/\/doi.org\/10.1007\/s00705-025-06381-8","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not disclosed any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}